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Background: Tobacco smoking leads to lung cancer. Approxi-
mately 10% of patients with lung cancer are life long never-smokers.
There are only limited data available on the clinical characteristics
and outcomes of lung cancer in never-smokers from the Western
hemisphere.
Methods: Demographic and survival information was collected on
254 never-smokers with a confirmed pathologic diagnosis of non-
small cell lung cancer (NSCLC) by reviewing their medical records
and the Social Security database.
Results: The study population consisted of 182 (71.6%) women and 72
(28.3%) men. The median age was 70 years (range: 31–91 years).
Adenocarcinoma was the most common histology accounting for
60.8% of all patients, followed by NSCLC not otherwise specified
(14.4%), bronchoalveolar carcinoma (13.6%), squamous cell carcinoma
(8.8%), and large-cell type (2.4%). Majority of patients presented with
stage III or IV disease (62.5%). We compared survival between never-
smokers and smokers with NSCLC matched for gender, histology,
tumor stage, and years of diagnosis. No significant difference in 5-year
survival was seen between never-smokers (27.2%) and smokers with
NSCLC (31.3%; p  0.73).
Conclusions: Two thirds of patients with lung cancer who report no
history of tobacco smoking are women. In the matched case–control
analysis, we report no significant survival difference between lung
cancer in never-smokers and those with history of tobacco smoking
and lung cancer.
Key Words: Non-small cell lung cancer, Never-smoker, Outcomes,
Presentation.
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Lung cancer is the leading cause of cancer related mortalityin the United States, and tobacco smoking is the main risk
factor for lung cancer.1 It accounts for more than 90% of lung
cancer in men and 75% to 85% in women in the United States
and Northern Europe.2,3 Nevertheless, 10% to 15% of all
newly diagnosed patients with lung cancer are never-smok-
ers.1 This subgroup of lung cancer patients has higher re-
sponse rates compared with those with history of tobacco
smoking when treated with inhibitors of epidermal growth
factor receptor tyrosine kinase (EGFR-TK), such as gefitinib
and erlotinib.4–7 The advent of EGFR-TK inhibitors in lung
cancer chemotherapy has directed attention to lung cancer in
never-smokers (LCINS) as never before. In addition, it has
been reported that activating mutations in the EGFR-TK
domain that predict treatment response is significantly higher
in LCINS when compared with tobacco-associated lung can-
cer (TALC).8,9
Distinctive molecular features have been described in
LCINS including 16p chromosomal aberration, variations in
the mutational spectrum of p53, and lower methylation rates
have been identified in LCINS.8–15 These genetic markers
indicate that the carcinogenesis pathway for LCINS may
differ from TALC.9,13,16 Several studies involving LCINS
report predominance of adenocarcinoma subtype and a gen-
der reversal with a higher proportion of women compared
with TALC. Only very little is known about the clinical out-
comes of patients with lung cancer who are life long never-
smokers, particularly from the Western hemisphere.17,18 There-
fore, we conducted this retrospective study to identify the
presenting features and stage specific outcomes in patients with
LCINS. For survival analysis, we conducted a one to one
matched case control analysis to compare survival between
patients with LCINS and TALC.
MATERIALS AND METHODS
The study involved 2762 consecutive patients with
non-small cell lung cancer NSCLC (all stages) diagnosed and
treated at the Washington University School of Medicine
(WUSM) Siteman Cancer Center from 1992 to 2002. The
WUSM Siteman Cancer Center is a major tertiary referral
center for cancer care and the patient population is predom-
inantly from the midwestern United States. The case records
on all these patients were retrieved. Of these 2762 patients,
254 were determined to be never-smokers with a confirmed
pathologic diagnosis of NSCLC. Patients with NSCLC who
were current or former smokers were excluded.
A never-smoker was defined as one who had never
smoked and was stated as such in the attending physician’s
notes. The smoking status information was drawn from the
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medical oncology charts and was verified from additional
sources when possible. The information collected on the 254
patients included demographic information, histopathology,
staging information, treatment, response to treatment, date of
last follow-up or date of death. Mortality data were collected
from several sources including tumor registry data, physi-
cian’s office charts, and the Social Security database. Overall
survival was determined as the duration from the date of
diagnosis to the date of death. Patients who were disease free
were censored at the date of last clinical contact.
We had complete presentation and outcomes informa-
tion on 221 LCINS. For survival analysis, we matched these
221 patients with LCINS (cases) to patients with confirmed
smoking status (controls). The controls were also drawn from
the WUSM tumor registry and included all smokers with
NSCLC seen between 1992 and 2002. The two groups were
matched for gender, histology, tumor stage, and time of
diagnosis. The time of diagnosis for each control had to be
within four years (arbitrarily chosen) from the time of diag-
nosis for the corresponding case. Overall survival in the two
groups was estimated using Kaplan–Meier product limit
method and compared with a Cox proportional hazards model
for clustered survival data.19
RESULTS
This study population consisted of 254 patients with
LCINS, of whom 182 (71.6%) were women and 72 (28.3%)
were men (Table 1). The median age was 70 years (range:
31–91 years). The study group had 215 Caucasians (84.9%),
32 (12.6%) African Americans, and 6 (2.4%) of Asian de-
scent. Adenocarcinoma was the most common histologic
subtype, with 152 (60.8%) patients; bronchoalveolar, 34
(13.6%); squamous cell carcinoma, 22 (8.8%); and large-cell,
6 (2.4%). Histologic subtype determination was unavailable
in 36 (14.4%) patients and was classified as NSCLC.
Staging information was available for 248 of the 254
patients with LCINS; 72 (28.3%) had stage I disease, 17
(6.7%) had stage II disease, 66 (25.9%) had stage III disease,
and 93 (36.6%) had stage IV disease at the time of presen-
tation. The most common site of metastasis was to the bone
in 37 (35.6%) patients, followed by the central nervous
system in 31 (29.8%) patients, the lung and pleura in 31
(29.8%) patients, and solid organs in 23 (22.1%) patients.
Information on treatment with chemotherapy and radiation
was available in 220 patients; 88 (34.6%) had received
chemotherapy, and 84 (33.1%) had received radiation therapy
as a part of their first-line treatment. None of the patients
included in this study received EGFR-TK inhibitors.
The 5-year survival estimate for the cases (221 patients
with LCINS) was 27.2% compared with 31.3% for the
controls (221 patients with TALC); the difference was not
statistically significant (p  0.73; Figure 1) The results did
not change after adjusting for age at diagnosis for the two
groups. The stagewise distribution of 5-year survival between
the two groups did not show any significant differences.
(Table 2) To validate the results of the case–control analysis
we compared the 5-year survival of the patients with LCINS
against a one-to-one matched unique second control group,
and no significant survival difference was detected.
We also reviewed the presentation characteristics and
outcomes of all NSCLC seen at our institution from 1992 to
2002. We compared the characteristics of the LCINS group
and the control group against the entire NSCLC patient
cohort (Tables 1 and 2). Our comparison identified a clear
predominance of women and adenocarcinoma subtype in
patients with LCINS.
DISCUSSION
The well-known reversal in gender distribution, with a
higher proportion of women in LCINS (unlike the more
common TALC), was observed once again in our study.2,3,20
In North America and Europe, more than 90% of all men with
lung cancer are tobacco smokers, whereas in women it ranges
from 75% to 85%.2 The prevalence of tobacco smoking
among men with newly diagnosed lung cancer in the Asian
population is similar to that of North America and Europe.
Nevertheless, the prevalence of tobacco smoking among Asian
women with newly diagnosed lung cancer is much lower com-
pared with their Western counterparts, ranging between 25%
and 56%.3,21–23 The predominance of adenocarcinoma (61%)
reported in our study is consistent with results reported in other
published studies, ranging from 76% to 47%.3,18,24–28 It has been
reported that the incidence of adenocarcinoma is more or less
uniform among never-smoker women of different geographical
regions.3
It is unclear whether patients with lung cancer who are
lifelong never-smokers present with metastatic disease at
presentation more often than those with history of tobacco
TABLE 1. Characteristics of Study Population
All Patients LCINS
Total subjects 2762 254
Median age (yr) 66.5 70
Gender
Female 1197 (43.3%) 182 (71.6%)
Male 1564 (56.6%) 72 (28.3%)
Race
Caucasian 2198 (79.6%) 215 (84.9%)
African American 540 (19.5%) 32 (12.6%)
Asian 13 (0.5%) 6 (2.4%)
Other/unknown 11 (0.4%) —
Histology
Adenocarcinoma 1226 (44.4%) 152 (60.8%)
Squamous cell carcinoma 1177 (43.2%) 22 (8.8%)
Bronchoalveolar carcinoma 134 (4.9%) 34 (13.6%)
Large-cell carcinoma 72 (2.6%) 6 (2.4%)
NSCLC 137 (4.9%) 36 (14.4%)
Stage
Stage I 853 (30.9%) 72 (28.3%)
Stage II 261 (9.4%) 17 (6.7%)
Stage III 870 (31.5%) 66 (25.9%)
Stage IV 707 (25.6%) 93 (36.6%)
Unknown 71 (2.6%)
LCINS, lung cancer in never-smokers; NSCLC, non-small cell lung cancer.
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smoking. In our study, there was a slight predominance in
stage IV disease (36.6%) in patients with LCINS versus all
patients with NSCLC (25.6%) at presentation. In a chart
review of consecutive patients (n  654) with adenocarci-
noma of the lung, there was no significant difference in the
proportion of stage IV disease between never-smokers (35%)
and smokers (39%).17 In an Asian study, the proportion of
stage IV disease at presentation was higher in patients with
LCINS versus patients with TALC (51.8% versus 42%; p 
0.002).22 The study by Dibble and colleagues18 reported a
greater proportion of distant-stage disease in LCINS than in
patients with TALC (71% versus 56%). Thus, it is unclear
whether a greater proportion of patients with LCINS present
with metastasis than patients with TALC. It may be that this
difference is more prominent in the Asian population than in
Caucasians. It is unknown whether there is any distinct
pattern of metastasis in LCINS. In our study, bone is the most
common site of metastasis, followed by brain and lung, and
then pleura.
The presentation characteristics of the entire cohort of
2762 patients with NSCLC are different from the LCINS
group (Table 1). In patients with NSCLC seen at WUSM
Siteman cancer center, there has been a significant increase in
the number of stage IV patients after January 1, 2000 (37%
versus 30%; p  0.0001).29 In addition, there has been a
decrease in squamous cell cancer histology after January 1,
2000 (24% versus 34%; p  0.001) and an increase in
women with NSCLC (46% versus 42%; p  0.005; un-
published data).
On the basis of our literature review, we identified four
studies comparing survival between LCINS and TALC. Of
these four studies, three reported better survival in LCINS
versus TALC. Nordquist and colleagues17 conducted an in-
stitutional retrospective study comparing survival between
never-smokers and smokers with adenocarcinoma (all
stages). They reported better 5-year survival in never-smok-
ers (n  132) compared with current smokers (n  522; 23%
versus 16%; p  0.004). Multivariate analysis identified
smoking status as an independent prognostic factor (p 
0.0245). Toh and colleagues22 reported the risk of death to be
higher in patients with TALC than patients with LCINS after
adjusting for sex, Eastern Cooperative Oncology Group sta-
tus, AJCC stage, comorbidities, weight loss, and treatment
received (hazards ratio 1.3; 95% CI, 1.04–1.62). The Utah
study reported a 3-year survival of 9.3% in never-smokers
versus 3.2% in smokers with NSCLC for all stages (no p
value given).18 Nevertheless, it is not known whether the
authors had controlled for the effect of confounding from
gender, stage, and histology. Another study, from Singapore,
has reported no significant difference in median overall sur-
vival between never-smokers and smokers.30
In our survival analysis, we did not find a significant
difference in survival between LCINS and TALC. By using a
matched case–control approach, we were able to eliminate
the confounding effects of stage, gender, and histology. We
did not control for treatment and comorbidities, because these
data were unavailable on many of the patients. Nevertheless,
we believe the inclusion of the year of diagnosis and using a
second unique control significantly minimizes the risk of
confounding from those variables. While our study findings
indicate that the presentation characteristics of patients are
different from patients with TALC, we did not find any
significant survival difference between these two groups.
FIGURE 1. Kaplan–Meier survival curve for lung cancer in never-smokers (LCINS; cases) versus tobacco-associated lung cancer
(TALC; controls).
TABLE 2. Five-year Survival by Stage
Stage
All
Patients (%) LCINS (%) TALC (%)
I 51.3 63.5 62.8
II 38.8 33.3 42.4
III 13.6 12.4 26.6
IV 2.8 3.8 5
LCINS, lung cancer in never-smokers; TALC, tobacco-associated lung cancer.
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Current evidence suggests that LCINS and TALC have
significant biological differences, although with conventional
therapy alone there might be no difference in survival between
the two groups. It is well known that treatment with EGFR-TKIs
results in significantly better outcomes in LCINS.4,6 On the basis
of current evidence, it has been proposed that the EGFR and
K-ras mutations are mutually exclusive to each other in lung
cancer. The EGFR-gene mutation may play a key role in the
carcinogenesis pathway in a significant proportion of LCINS,
whereas in smokers K-ras mutation might have a similar role.31
Other studies have also identified significant differences in the
molecular genetics of LCINS and TALC.16,19,32–33 Therefore, a
targeted approach based on a better understanding of the mo-
lecular pathways, such as first-line treatment with EGFR-TKIs
in never-smokers, may yield better results than would conven-
tional chemotherapy alone. The CALGB 30406 study is cur-
rently evaluating the role of erlotinib in treatment naı¨ve patients
with NSCLC who are never-smokers/light former smokers. It is
likely that in future the systemic therapy for LCINS may be
distinctly different compared with TALC. Further investigations
are required to characterize the molecular genetic differences
between LCINS and TALC and to identify potential therapeutic
targets and prognostic markers.34
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